{"filings":[{"id":472120,"accession_number":"0001477932-26-003241","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-05-15T20:45:22+00:00","items":["5.02"],"status":"ready","headline":"Director Mickie Henshall not standing for re-election; board reduces to 7 directors","event_type":"leadership","confidence":"high","bullets":["Mickie Henshall notified board she will not stand for re-election at the 2026 Annual Meeting.","No disagreement with the company on operations, policies, or practices.","Board size reduced from eight to seven directors, effective before the 2026 Annual Meeting.","Ms. Henshall had served on the board since August 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443040,"accession_number":"0001477932-26-003126","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-05-14T20:18:53+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx Q1 2026 revenue $1.0M; $5M milestone potential from feline lymphoma test","event_type":"earnings","confidence":"high","bullets":["Revenue of $1.0M in Q1 2026 vs $0.2M in Q1 2025; operating loss decreased 3% YoY.","Net cash used in operations was $5.3M; raised $5.4M from ATM equity and $1.9M from convertible note.","Received $1M in non-dilutive Walloon Region funding; ~$0.9M more expected over 12 months.","Feline lymphoma assay manuscript submitted for peer review; expected to unlock $5M milestone payment.","Discussions ongoing with >12 diagnostic companies for licensing; Nu.Q Lung Cancer reimbursement in France progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":985076.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99883,"accession_number":"0001477932-26-002619","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"VolitionRx completes 1-for-20 reverse stock split effective April 28, 2026","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at special meeting March 31, 2026; Board set ratio at 1:20.","Certificate of Amendment filed with Delaware on April 27, 2026, effective 12:01 a.m. ET April 28, 2026.","Reverse split applies to all outstanding common shares; fractional shares treated per amendment.","Common stock continues trading on NYSE American under ticker VNRX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99882,"accession_number":"0001477932-26-002472","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"NYSE American accepts VolitionRx compliance plan; shares continue trading until Aug 2027 review","event_type":"regulatory","confidence":"high","bullets":["Received non-compliance notice on Feb 6, 2026 for stockholders' equity deficiency (below $2M threshold).","Compliance plan submitted by March 8, 2026; accepted by NYSE American on April 22, 2026.","Company has until August 6, 2027 to regain compliance; subject to periodic NYSE American review.","If plan progress insufficient or compliance not met by deadline, delisting proceedings may be initiated.","No immediate impact on listing; common stock continues trading under symbol VNRX on NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99881,"accession_number":"0001477932-26-002373","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["8.01","5.07"],"status":"ready","headline":"VolitionRx board approves 1-for-20 reverse stock split effective April 28, 2026","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio set at 1-for-20, effective 12:01 a.m. ET on April 28, 2026.","No fractional shares; holders receive one whole share for any fractional interest.","Proportional adjustments to outstanding warrants, options, awards, and convertible notes.","Split follows shareholder approval at March 31, 2026 special meeting; tied to Lind Global financings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99880,"accession_number":"0001477932-26-001940","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"VolitionRx shareholders approve share issuance to Lind Global and reverse stock split authorization","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (issuance >20% to Lind Global): 44.15M for, 14.10M against, 1.11M abstain, 21.15M broker non-votes approved.","Proposal 2 (reverse split authorization): 62.84M for, 16.45M against, 1.22M abstain; board may choose ratio 1:5 to 1:20.","Record date Feb 9, 2026: 135.57M shares outstanding; 80.51M shares present at special meeting on March 31, 2026.","No other matters were presented for stockholder action at the special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116158,"accession_number":"0001477932-26-001830","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx FY2025 revenue up 40% to $1.7M; net loss down 14%","event_type":"earnings","confidence":"high","bullets":["Full-year revenue $1.7M (+40% YoY); Q4 revenue growth 133% vs prior year.","Operating expenses down $4.8M (17%); net cash used in ops $19.7M (-24%).","Received first order for Nu.Q Cancer assays for lung cancer clinical certification.","Nu.Q NETs assay included in French government-backed sepsis study (~$7.3M).","Subsequent to year end: raised $5.4M ATM equity, $1.9M convertible note, $1.0M non-dilutive."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":985076.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116157,"accession_number":"0001477932-26-000955","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"VolitionRx issues 6.4M shares to Lind Global to satisfy $1.42M debt payments","event_type":"other_material","confidence":"high","bullets":["Feb 17, 2026: issued 1,956,178 shares to Lind Global for $416,666 payment.","Jan 29, 2026: issued 2,569,753 shares for $583,334 payment.","Jan 16, 2026: issued 1,893,936 shares for $416,666 payment.","Shares issued under Section 4(a)(2) / Rule 506 exemption; no commissions or public offering.","Also notes Sep 2025 private placement: 483,870 shares + warrants at $0.62/unit for $300,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116156,"accession_number":"0001477932-26-000714","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"VolitionRx receives NYSE American non-compliance notice for stockholders' equity; must submit plan by March 8, 2026","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American notice on Feb 6, 2026 for failing $2M, $4M, $6M stockholders' equity thresholds due to sustained losses.","Must submit compliance plan by March 8, 2026; deadline to regain compliance is August 6, 2027.","Stock will trade under VNRX with \".BC\" designation indicating \"below compliance.\"","If plan not submitted or accepted, NYSE American will commence delisting proceedings.","No immediate impact on listing or business operations; company intends to submit a plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116155,"accession_number":"0001477932-26-000107","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"VolitionRx secures $2.0M funding from Lind Global with convertible note and warrants","event_type":"debt","confidence":"high","bullets":["Gross proceeds $2M; issues $2.4M senior secured convertible note and 7,000,350 warrants at $0.5714/share.","Note has 18 monthly payments of $133,333 beginning 6 months after issuance; no interest accrues.","Lind may increase up to 2 monthly payments to $1M each on notice.","This is additional to existing $7.5M note from May 2025 with Lind.","Company must file resale registration statement within 30 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132608,"accession_number":"0001477932-25-008932","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"VolitionRx subsidiary CEO Dr. Butera to depart Jan 31, 2026; position eliminated","event_type":"leadership","confidence":"high","bullets":["Volition Veterinary CEO Dr. Salvatore Thomas Butera given termination notice, effective Jan 31, 2026.","CEO position eliminated as part of ongoing cost-realignment efforts; duties redistributed.","Dr. Butera expected to stay as part-time consultant post-termination under agreed terms.","Departure not due to any disagreement with company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132607,"accession_number":"0001477932-25-008182","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx Q3 revenue up 32% to $0.6M; signs deals with Werfen and Hologic","event_type":"earnings","confidence":"high","bullets":["Revenue $0.6M (+32% YoY); net loss down 8% YoY; operating expenses down 10% YoY.","Net cash used in ops $3.6M (-33% YoY); post-quarter raised $6.1M net from public offering.","Signed Research License and Option Agreement for APS with Werfen; Co-Marketing Agreement with Hologic.","In discussions with ~10 leading diagnostic/liquid biopsy companies for further licensing deals.","Anticipates peer-reviewed publications on Nu.Q platform and Capture-Seq technology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":1280350.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132604,"accession_number":"0001477932-25-008179","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K/A","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"VolitionRx amends over-allotment terms; underwriter buys 1.19M shares and 1.73M warrants","event_type":"other_material","confidence":"high","bullets":["Amendment permits separate exercise of over-allotment shares and warrants, not just combined.","Underwriter exercised over-allotment: 1,194,000 shares at $0.51 and 1,732,500 warrants at $0.01.","Net proceeds to VolitionRx of $582,426 after 7.0% underwriting discount and expenses.","Underwriter also received warrants to buy 83,580 shares at $0.63, exercisable after 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132603,"accession_number":"0001477932-25-008019","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K/A","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"VolitionRx amends underwriting agreement; over-allotment partially exercised for 1.194M shares and 1.7325M warrants","event_type":"other_material","confidence":"high","bullets":["Amendment allows Over-Allotment Option to be exercised separately for shares and/or warrants, not combined.","Underwriter exercised Over-Allotment for 1,194,000 shares and 1,732,500 warrants (warrants for 83,580 shares).","Combined offering price was $0.52 per share and $0.01 per warrant; underwriting commission 7.0%.","Original offering closed Oct 10, 2025: 11,550,000 shares and warrants at same terms.","Amendment corrects typographical errors in original Exhibit 1.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132606,"accession_number":"0001477932-25-007984","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"VolitionRx over-allotment exercised: 1.19M shares & 1.73M warrants sold at $0.52/unit","event_type":"other_material","confidence":"high","bullets":["Underwriter exercised over-allotment option for 1,194,000 shares and 1,732,500 warrants at $0.52 per unit.","Amendment to Underwriting Agreement permits separate exercise of over-allotment for shares and warrants.","Total shares offered increased to 12,744,000; total warrants to 13,282,500.","Gross proceeds from over-allotment approximately $626,325 before 7% underwriting discount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132605,"accession_number":"0001477932-25-007544","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"VolitionRx raises $6M in underwritten offering; only $0.3M cash pre-offering","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $6.0M from 11.55M units at $0.52; net ~$5.4M after underwriting discounts and expenses.","Each unit contains one share and one warrant; warrants exercisable at $0.60, 5-year term, cashless basis if no registration.","Pre-offering cash and cash equivalents estimated at only $0.3M as of September 30, 2025.","Offering closed October 14, 2025; directors and officers purchased 254,229 units on same terms.","Proceeds to fund R&D, clinical studies, product commercialization, working capital, and potential strategic acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149136,"accession_number":"0001477932-25-005919","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx Q2 2025 revenue ~$0.4M; net loss down 11% YoY; expects first human licensing deal","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue just over $0.4M; H1 2025 revenue up 15% YoY.","Net loss decreased 11% in Q2 and 24% in H1 vs prior year; operating cash burn down 30% to $10.6M in H1.","Cash & equivalents $2.3M at June 30, 2025; received $1.2M from direct offering post-quarter (director participation).","Management expects first human diagnostics out-licensing deal in Q3 2025; confidential discussions with >10 companies.","Conference call scheduled for August 15, 2025 at 8:30 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":653073.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149135,"accession_number":"0001477932-25-005422","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"VolitionRx raises $1.21M in registered direct offering; insiders buy stock","event_type":"other_material","confidence":"high","bullets":["156,250 shares sold to directors/officers at $0.64/share; 1,734,375 shares + warrants at $0.64/unit.","Gross proceeds of $1.21M; potential additional $1.3M from warrants at $0.768/share.","Warrants exercisable for 5 years from Aug 2025; insiders receive no warrants.","No placement agent; offering expected to close Aug 5, 2025.","Net proceeds for R&D, product development, clinical studies, working capital, and potential M&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168134,"accession_number":"0001477932-25-004721","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"VolitionRx shareholders approve authorized share increase to 325M; all director nominees elected","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 175M to 325M effective June 18, 2025, via Certificate of Second Amendment.","All eight director nominees elected with ~35-36M votes for each; about 14.7M broker non-votes.","Ratification of Sadler, Gibb & Associates as auditor passed with 51.3M votes for, 330k against.","Non-binding advisory vote on named executive officer compensation passed with 34.4M for, 2.3M against.","Charter amendment proposal passed with 49.5M votes for, 1.8M against, and 385k abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}